Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children

Journal of Infectious Diseases

Volumn 194, Issue 3, 2006, Pages 370-376

  Vesikari, Timo ^a   Karvonen, Aino V ^a   Majuri, Jukka ^a   Zeng, Shang Qin ^a   Pang, Xiao Li ^a   Kohberger, Robert ^b   Forrest, Brace D ^b   Hoshino, Yasutaka ^c   Chanock, Robert M ^c   Kapikian, Albert Z ^c  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b WYETH RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC AGENT; BOVINE HUMAN ROTAVIRUS REASSORTANT TETRAVALENT VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PLACEBO; RHESUS RHESUS HUMAN ROTAVIRUS REASSORTANT TETRAVALENT VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FEMALE; FEVER; GASTROENTERITIS; HUMAN; IMMUNITY; IMMUNOGENICITY; INFANT; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; VIRUS INFECTION;

ANIMALS; CATTLE; DOUBLE-BLIND METHOD; FEMALE; FINLAND; GASTROENTERITIS; HUMANS; ILEAL DISEASES; INFANT; INFANT, NEWBORN; INTUSSUSCEPTION; MACACA MULATTA; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 33746362943     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505151     Document Type: Article

References (30)

1. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:577-81.
2. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 1999; 48:1007.
3. Spiegel J. Department of Health and Human Services, National Institutes of Health. Prospective grant of exclusive license: vaccines against rotavirus disease. Federal Register 2003; 68:1576-77.
4. Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-9.
5. Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998; 17:334-40.
6. Kapikian AZ, Hoshino Y, Flores J, et al. Alternative approaches to the development of a rotavirus vaccine. In: Holmgren J, Lindberg A, Mollby R, eds. Development of vaccines and drugs against diarrhea. 11th Nobel Conference, Stockholm 1985. Lund, Sweden: Studentlitteratur, 1986: 192-214.
7. Pérez-Schael I, Guntiñas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997;337:1181-7.
8. Vesikari T, Isolauri E, Delem A, d'Hondt E, André FE, Zissis G. Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 1983; 2:807-11.
9. Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am J Dis Child 1986; 140:350-6.
10. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153:832-9.
11. Clark HF, Offit PA, Ellis RW, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174(Suppl 1):S73-80.
12. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985; 53:949-54.
13. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986; 24:822-6.
14. Clements-Mann ML, Makhene MK, Mrukowicz J, et al. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 1999; 17:2715-25.
15. Clements-Mann ML, Dudas R, Hoshino Y, et al. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 2001; 19:4676-84.
16. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D × RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 1995; 13:310-2.
17. Wyatt RG, Greenberg HB, James WD, et al. Definition of human rotavirus serotypes of plaque reduction assay. Infect Immun 1982; 37:110-5.
18. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
19. Pang XL, Joensuu J, Hoshino Y, Kapikian AZ, Vesikari T. Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. J Clin Virol 1999; 13:9-16.
20. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 1995; 273:1191-6.
21. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97:7-13.
22. Santosham M, Moulton LH, Reid R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-7.
23. Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006; 25:118-22.
24. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
25. Joensuu J, Koskenniemi E, Vesikari T. Prolonged efficacy of rhesus-human reassortant rotavirus vaccine. Pediatr Infect Dis J 1998; 17:427-9.
26. Murphy BR, Morens DM, Simonsen L, et al. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 2003; 187:1301-8.
27. Simonsen L, Viboud C, Elixhausen A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at vaccination. J Infect Dis 2005;192(Suppl):S36-43.
28. Kapikian AZ, Simonsen L, Vesikari T, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005;192(Suppl):S22-9.
29. Rohrbaugh ML. Department of Health and Human Services, National Institutes of Health. Prospective grant of exclusive license: human-bovine reassortant rotavirus vaccine. Federal Register 2004;69:34381-2.
30. Ferguson SM. Department of Health and Human Services, National Institutes of Health. Prospective grant of partially exclusive licences: human-bovine reassortant vaccine. Federal Register 2004; 69:51335-6.